Tripep receives approval to commence microdosing study

Tripep receives approval to commence microdosing study Tripep has received approval to conduct the planned microdosing study with alphaHGA, Tripep's new HIV candidate drug. The study, which will be performed on human non-infected volunteers, will give valuable information on alphaHGA's bioavailability, i.e. how alphaHGA is taken up after oral administration and how long the drug remains in the body. The study, which will start on June 4th, will be conducted in Nottingham, England, by Pharmaceutical Profiles Ltd, a leading contract research organisation, and is expected to take approximately 4 weeks. In order to conduct the study, approval from both the local ethical committee and from the Medical and Healthcare products Regulatory Agency (MHRA) were required. These approvals have now been obtained. - "This is the first time alphaHGA will be tested in humans. The results from this microdosing study will guide us in designing the future efficacy studies for alphaHGA in HIV-infected patients, which are planned to be performed later this year", says Professor Anders Vahlne, Head of Research at Tripep. For more information, please contact: Anders Vahlne, Head of Research Phone +46 8-5858 1313, mobile +46 709-28 05 28 E-mail: anders.vahlne@labmed.ki.se Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies: -research and development of alphaHGA, a HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS® technology platform. -producing vaccines against influenza, allergies and Alzheimer's disease through associated company VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/06/02/20040602BIT20270/wkr0007.pdf http://www.waymaker.net/bitonline/2004/06/02/20040602BIT20270/wkr0009.doc

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe